Cassava Sciences SAVA shares are trading higher on Wednesday after the company announced additional data from the Phase 2b study of sumifilam in patients with Alzheimer's disease. Patients treated with it showed a statistically significant treatment benefit.
Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. It is also developing an experimental biomarker diagnostic PTI-125 to detect Alzheimer's disease with the help of a blood test.
Cassava Sciences shares were trading up 23.75% at $11.37 on Wednesday. The stock has a 52-week high of $12.68 and a 52-week low of $1.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
